# US 2025/0145628 A1 · Pyrazolopyrimidines, compositions comprising them and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145628 A1
- Document ID: US20250145628A1
- Status: Published application
- Kind: A1
- Application number: 18/837,928
- Filed: 2023-02-02
- Published: 2025-05-08
- Earliest claimed: 2022-02-15
- Applicants: Novo Nordisk A/S
- Inventors: Jeremy Green; Shawn Gallagher-Duval; Alexandre Lemire; Yuchen Zhou; Hong Wang
- Web page: https://patentgrep.com/patent/US20250145628A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- C07B 59/002: {Heterocyclic compounds}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present document relates to pyrazolopyrimidine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the pyrazolopyrimidine compounds, or a tautomeric form and/or salt thereof, are of Formula I: Formula I wherein R1 to R4 are as defined herein.

## Claims

### Claim 1

A compound of Formula I:
wherein,
R1 and R2 are each independently selected from optionally substituted C6-10aryl and optionally substituted C5-10heteroaryl;
R3 is selected from optionally substituted C1-12alkyl, optionally substituted C1-12alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted C3-10cycloalkyl, optionally substituted C3-10heterocycloalkyl, optionally substituted C6-10aryl, and optionally substituted C5-10heteroaryl, optionally substituted —X1—C3-10cycloalkyl, optionally substituted —X1—C3-10heterocycloalkyl, optionally substituted —X1—C6-10aryl, and optionally substituted —X1—C5-10heteroaryl;
R4 is selected from NH2, optionally substituted C1-12alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted C3-10cycloalkyl, optionally substituted C3-10heterocycloalkyl, optionally substituted —X2—C3-10cycloalkyl, and optionally substituted —X2—C3-10heterocycloalkyl;
X1 is selected from O and NR5, wherein R5 is H or an optionally substituted C1-6alkyl; and
X2 is selected from O and NR6, wherein R6 is H or an optionally substituted C1-6alkyl;
or an isomer and/or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R4 is NH2.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R4 is selected from optionally substituted C1-12alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted C3-10cycloalkyl, optionally substituted C3-10heterocycloalkyl, optionally substituted —X2—C3-10cycloalkyl, and optionally substituted —X2—C3-10heterocycloalkyl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R4 is an optionally substituted C1-12alkoxy, preferably optionally substituted C1-6alkoxy, more preferably optionally substituted C1-4alkoxy.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R4 is an optionally substituted C1-12alkylamino or C1-12dialkylamino, preferably optionally substituted C1-6alkylamino or C1-6dialkylamino, more preferably optionally substituted C1-4alkylamino or C1-4dialkylamino.

### Claim 6 (depends on 4)

The compound of claim 4, wherein said alkyl or alkoxy is substituted with at least one group selected from OH, CO2H, CO2NH2, CO2NHC1-6alkyl, CO2N(C1-6alkyl)2, P(O)(C1-6alkyl)2, NHC(O)C1-6alkyl, N(C1-6alkyl)C(O)C1-6alkyl.

### Claim 7 (depends on 3)

The compound of claim 3, wherein R4 is an optionally substituted C3-10cycloalkyl or optionally substituted C3-10heterocycloalkyl, preferably optionally substituted C3-6cycloalkyl or optionally substituted C3-6heterocycloalkyl, more preferably optionally substituted C4-5cycloalkyl or optionally substituted C4-5heterocycloalkyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein said heterocycloalkyl is linked to the pyrazolopyrimidine core through a nitrogen atom from the heterocycloalkyl.

### Claim 9 (depends on 7)

The compound of claim 7, wherein said heterocycloalkyl is selected from pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl groups.

### Claim 10 (depends on 3)

The compound of claim 3, wherein R4 is an optionally substituted —X2—C3-10cycloalkyl or optionally substituted —X2—C3-10heterocycloalkyl.

### Claim 11 (depends on 3)

The compound of claim 3, wherein X2 is NR6, preferably wherein R6 is H or C1-3alkyl.

### Claim 12 (depends on 7)

The compound of claim 7, wherein said cycloalkyl or heterocycloalkyl is substituted with at least one group selected from OH, CO2H, CO2NH2, CO2NHC1-6alkyl, CO2N(C1-6alkyl)2, P(O)(C1-6alkyl)2, NHC(O)C1-6alkyl, N(C1-6 alkyl)C(O)C1-6alkyl, each optionally substituted, and wherein said group is optionally linked to the cycloalkyl or heterocycloalkyl through a C1-6alkyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R3 is an optionally substituted C1-6alkyl group, optionally substituted C1-6alkoxy, or an optionally substituted C1-6alkylamino or diC1-6alkylamino.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R3 is an optionally substituted C6aryl, C5-6heteroaryl, C4-7cycloalkyl or C4-7heterocycloalkyl group, or a C6aryl, C5-6heteroaryl, C4-7cycloalkyl or C4-7heterocycloalkyl linked to the pyrazolopyrimidine core through X1.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the aryl group is of the formula:
wherein,
R7 is independently in each occurrence selected from halogen, OH, OR9, CN, NO2, C(O)R9, C(O)N(R8)2, C(R10)=NR10, SO2R9, SO2N(R8)2, N(R10)C(O)R9, N(R10)SO2R9, N(R10)C(O)N(R8)2, N(R10)SO2N(R8)2, N(R8)2, P(O)(R8)2, P(O)(OR8)2, B(OR8)2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, and C4-10heterocycloalkyl;
R3 is independently in each occurrence selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C4-10heterocycloalkyl, C6aryl, and C5-10heteroaryl, or two R3 are taken together with their adjacent atom(s) to form a C4-10heterocycloalkyl group;
R9 is independently in each occurrence selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl;
R10 is independently in each occurrence selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl; and
c is 0, 1, 2, 3, 4 or 5;
wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally further substituted.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R7 is selected from CN, an optionally substituted C1-6alkyl group, and OR9, wherein R9 is an optionally substituted C1-6alkyl group.

### Claim 17 (depends on 14)

The compound of claim 14, wherein the aryl or heteroaryl group is of the formula:
wherein,
X3, X4, X5, X6, and X7 are each independently selected from N and CR11, wherein at most three of X3, X4, X5, X6, and X7 are N, or wherein one of two adjacent X3, X4, X5, X6, and X7 is absent and the other is O, S or NR10;
R3 is independently in each occurrence selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C4-10heterocycloalkyl, C6aryl, and C5-10heteroaryl, or two R3 are taken together with their adjacent atom(s) to form a C4-10heterocycloalkyl group;
R9 is independently in each occurrence selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl;
R10 is independently in each occurrence selected from H, C1-6alkyl, C2-alkenyl, C2-alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl; and
R11 is independently in each occurrence selected from hydrogen, halogen, OH, OR9, CN, NO2, C(O)R9, C(O)N(R8)2, C(R10)=NR10, SO2R9, SO2N(R8)2, N(R10)C(O)R9, N(R10)SO2R9, N(R10)C(O)N(R8)2, N(R10)SO2N(R8)2, N(R8)2, P(O)(R8)2, P(O)(OR8)2, B(OR8)2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, and C4-10heterocycloalkyl;
wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally further substituted.

### Claim 18 (depends on 17)

The compound of claim 17, wherein one of X3, X4, X5, X6, and X7 is N.

### Claim 19 (depends on 18)

The compound of claim 18, wherein X4 is N and X3, X6, and X7 are each CH.

### Claim 20 (depends on 17)

The compound of claim 17, wherein X5 is CR11 and R11 is selected from CN, an optionally substituted C1-6alkyl group (e.g., CH3, CF3, etc.), and OR9, wherein R9 is an optionally substituted C1-6alkyl group.

### Claim 21 (depends on 14)

The compound of claim 14, wherein the cycloalkyl or heterocycloalkyl group is of the formula:
wherein,
X8 is selected from N and CR11;
X9, X10, X11, X12, X13, and X14 are each independently selected from O, NR12, SO2, and C(R13)2, wherein at most two of X8, X9, X10, X11, X12, X13, and X14 are or comprise O, N or S, and/or wherein up to 3 of X9, X10, X11, X12, X13, and X14 are absent to form a 4, 5, or 6-membered ring, and/or two or three of X8, X9, X10, X11, X12, X13, and X14 are taken together to form a bridge through one to three additional bridging atoms, e.g. carbon atoms;
R8 is independently in each occurrence selected from H, C1-6alkyl, C2-6alkenyl, C2-alkynyl, C3-10cycloalkyl, C4-10heterocycloalkyl, C6aryl, and C5-10heteroaryl, or two R8 are taken together with their adjacent atom(s) to form a C4-10heterocycloalkyl group;
R9 is independently in each occurrence selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl;
R10 is independently in each occurrence selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl;
R11 is independently in each occurrence selected from hydrogen, halogen, OH, OR9, CN, NO2, C(O)R9, C(O)N(R8)2, C(R10)=NR10, SO2R9, SO2N(R8)2, N(R10)C(O)R9, N(R10)SO2R9, N(R10)C(O)N(R8)2, N(R10)SO2N(R8)2, N(R8)2, P(O)(R8)2, P(O)(OR8)2, B(OR8)2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, and C4-10heterocycloalkyl;
R12 is selected from is independently in each occurrence selected from hydrogen, C(O)R9, C(O)N(R8)2, SO2R9, SO2N(R8)2, P(O)(R8)2, P(O)(OR8)2, B(OR8)2, C1-6alkyl, C2-alkenyl, C2-6alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, and C4-10heterocycloalkyl; and
R13 is independently in each occurrence selected from hydrogen, halogen, OH, OR9, CN, NO2, C(O)R9, C(O)N(R8)2, C(R10)=NR10, SO2R9, SO2N(R8)2, N(R10)C(O)R9, N(R10)SO2R9, N(R10)C(O)N(R8)2, N(R10)SO2N(R8)2, N(R8)2, P(O)(R8)2, P(O)(OR8)2, B(OR8)2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, and C4-10heterocycloalkyl or two R13 are taken together with their adjacent atom(s) to form a C4-10cycloalkyl or C4-10heterocycloalkyl group;
wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally further substituted.

### Claim 22 (depends on 21)

The compound of claim 21, wherein X8 is N.

### Claim 23 (depends on 21)

The compound of claim 21, wherein X11 is NR12.

### Claim 24 (depends on 21)

The compound of claim 21, wherein X11 is C(R13)2.

### Claim 25 (depends on 21)

The compound of claim 21, wherein at least one R13 is independently in each occurrence selected from OH, OR9, C(O)N(R8)2, N(R10)C(O)R9, N(R8)2, and an optionally substituted C1-6alkyl.

### Claim 26 (depends on 21)

The compound of claim 21, wherein X12 is absent.

### Claim 27 (depends on 21)

The compound of claim 21, wherein X9 and X14 are absent.

### Claim 28 (depends on 1)

The compound of claim 1, wherein X1 is absent.

### Claim 29 (depends on 1)

The compound of claim 1, wherein X1 is present and is NR5, preferably wherein R5 is H.

### Claim 30 (depends on 1)

The compound of claim 1, wherein R2 is an optionally substituted C6aryl or optionally substituted C5-6heteroaryl.

### Claim 31 (depends on 30)

The compound of claim 30, wherein R2 is of the formula:
wherein,
X15, X16, X17, X18, and X19 are each independently selected from N and CR11, wherein at most three of X15, X16, X17, X18, and X19 are N, or wherein one of two adjacent X15, X16, X17, X18, and X19 is absent and the other is O, S or NR10;
wherein R10 is independently in each occurrence selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7heterocycloalkyl, C6aryl, and C5-6heteroaryl; and R11 is independently in each occurrence selected from hydrogen, halogen, OH, OR9, CN, NO2, C(O)R9, C(O)N(R8)2, C(R10)=NR10, SO2R9, SO2N(R8)2, N(R10)C(O)R9, N(R10)SO2R9, N(R10)C(O)N(R8)2, N(R10)SO2N(R8)2, N(R8)2, P(O)(R8)2, P(O)(OR8)2, B(OR8)2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, and C4-10heterocycloalkyl; and
wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally further substituted.

### Claim 32 (depends on 31)

The compound of claim 31, wherein X15, X16, X17, X18, and X19 are each CR11.

### Claim 33 (depends on 31)

The compound of claim 31, wherein X15 is CR11, wherein R11 is selected from halogen and OR9.

### Claim 34 (depends on 31)

The compound of claim 31, wherein X16, X17, X18, and X19 are each CR11, wherein R11 is hydrogen.

### Claim 35 (depends on 33)

The compound of claim 33, wherein R2 is a 2-methoxyphenyl or 2-chlorophenyl group.

### Claim 36 (depends on 31)

The compound of claim 31, wherein one of X15, X16, X17, X18, and X19 is N.

### Claim 37 (depends on 31)

The compound of claim 31, wherein X16 is N or CH.

### Claim 38 (depends on 31)

The compound of claim 31, wherein X17 is CR11, and wherein R11 is cyano, halogen, halogenated alkyl or OR9.

### Claim 39 (depends on 38)

The compound of claim 38, wherein R2 is a 4-cyanophenyl or 6-cyano-3-pyridyl group.

### Claim 40 (depends on 1)

The compound of claim 1, wherein R1 is an optionally substituted C6aryl.

### Claim 41 (depends on 40)

The compound of claim 40, wherein R1 is a 4-chlorophenyl group.

### Claim 42 (depends on 1)

The compound of claim 1, wherein the compound is selected from Compounds 1 to 78 as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The compound of claim 42, wherein the compound is selected from Compounds 1 to 77, as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 42)

The compound of claim 42, wherein the compound is Compound 78, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 43)

The compound of claim 43, wherein the compound is selected from Compounds 1-18, 20-31, 33-61, 63-68, and 70-77, or Compounds 1-18, 20-29, 31, 36-61, 63-68, and 70-77, as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 43)

The compound of claim 43, wherein the compound is selected from Compounds 1-17, 20-22, 25-27, 37, 38, 42-46, 48-61, 63-68, 70-77, as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 43)

The compound of claim 43, wherein the compound is selected from Compounds 1-5, 7-11, 13-15, 21, 22, 27, 42, 43, 45, 50-58, 60, 61, 63, 64, 70(R), 70(S), 71(S), 72(R), 72(S), as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 48 (depends on 43)

The compound of claim 43, wherein the compound is selected from Compounds 1, 2, 4, 7-9, 11, 13, 15, 21, 27, 43, 45, 50-53, 56-58, 60, 61, 63, 64, 70(R), 71(S), 72(R), 72(S), as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1, together with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim at position 50

-55. (canceled)

### Claim 56 (depends on 1)

A method for the treatment of a disorder selected from disorders related to appetite or their complications, disorders related to glucose regulation or their complications, fibrosis related disorders or their complications, disorders related to metabolism or their complications, disorders related to skin and hair growth and healing, disorders related to the GI tract, disorders related to obesity or their complications, or a combination thereof, comprising administering a compound as defined in claim 1 to a subject in need thereof.

### Claim 57 (depends on 56)

The method of claim 56, wherein said disorders related to appetite or their complications are selected from Prader-Willi Syndrome (PWS), hypothalamic obesity, pro-opiomelanocortin (POMC) deficiency (including POMC obesity, heterozygous POMC deficiency obesity, POMC epigenetic disorders), leptin receptor (LepR) deficiency, Bardet-Biedl (BB) syndrome, and Alström syndrome.

### Claim 58 (depends on 56)

The method of claim 56, wherein said disorders related to glucose regulation or their complications are selected from diabetes Type I, diabetes Type II, insulin resistance, pre-diabetes, pancreatic diseases (by β-cell protection and/or increased insulin production), and associated nephropathies, neuropathies and retinopathies.

### Claim 59 (depends on 56)

The method of claim 56, wherein said fibrosis related disorders or their complications are selected from progressive fibrosis associated with interstitial lung disease, idiopathic pulmonary fibrosis (IPF), Hermansky-Pudlak syndrome pulmonary fibrosis (HPS—PF), cirrhosis and other liver fibrosis disorders (such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, primary biliary cholangitis), skin fibrotic disorders (such as scleroderma), fibrotic renal diseases and chronic kidney diseases.

### Claim 60 (depends on 56)

The method of claim 56, wherein said disorders related to metabolism or their complications are selected from metabolic syndrome and hyperlipidemia (e.g. hyper-triglyceridemia, hyper-triglyceridemia in the setting of low HDL-cholesterol, elevation of LDL and/or total cholesterol and/or VLDL and/or elevated Apolipoprotein B, atherosclerotic cardiovascular disease, etc.).

### Claim 61 (depends on 56)

The method of claim 56, wherein said disorders related to obesity or their complications are selected from sleep apnea, snoring, asthma, pulmonary hypoventilation syndrome, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual irregularities, degenerative arthritis, venous statis ulcer, coronary artery disease, arterial sclerotic disease, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignancies of the liver, ovaries, cervix, uterus, breasts, prostate, or gallbladder.

### Claim 62 (depends on 56)

The method of claim 56, wherein said disorders of the skin and hair is selected from alopecia (male pattern baldness and alopecia associated with metabolic syndrome), excessive scar formation (cicatrix and keloid), and scleroderma.

### Claim 63 (depends on 56)

The method of claim 56, wherein said disorders related to the GI tract is selected from constipation, irritable bowel syndrome, and inflammatory bowel syndrome, including ulcerative colitis and Crohn's disease.

### Claim 64 (depends on 43)

The compound of claim 43, wherein the compound is selected from Compound 8, Compound 15, or Compound 45, as defined herein, or an isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 65

A compound which is selected from
